Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | ANPEP | P15144 | 3/20 | 0.49 |
| ▸ | DPP4 | P27487 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | ESR1 | P03372 | 7/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6307015 | 1.00 | MEN1 (0.56) | MEN1KMT2AANPEPDPP4LMNA | |
| SCHEMBL21976969 | 0.81 | ANPEP (0.55) | MEN1KMT2AANPEPDPP4ESR1 | |
| SCHEMBL6099472 | 0.81 | LMNA (0.69) | KMT2ALMNAHTTALDH1A1 | |
| SCHEMBL29923369 | 0.81 | LMNA (0.69) | KMT2ALMNAHTTALDH1A1 | |
| SCHEMBL22906690 | 0.78 | MEN1 (0.64) | MEN1KMT2AANPEPDPP4ESR1 | |
| SCHEMBL22906972 | 0.76 | MEN1 (0.68) | MEN1KMT2AANPEPDPP4ESR1 | |
| SCHEMBL24710720 | 0.75 | ANPEP (0.51) | MEN1KMT2AANPEPDPP4ESR1 | |
| SCHEMBL10914223 | 0.75 | ANPEP (0.50) | MEN1KMT2AANPEPDPP4ESR1 | |
| SCHEMBL3503488 | 0.73 | MAOB (0.48) | MEN1KMT2AMAOAMAOB | |
| SCHEMBL3503490 | 0.73 | MAOB (0.48) | MEN1KMT2AMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1277820-C | Phthalimido derivatives as inhibitors of monoamine oxidase B | HOFFMANN LA ROCHE (CH) | 2006-10-04 | — | — | CN | disclosed |
| CN-1642911-A | Phthalimido derivatives as inhibitors of monoamine oxidase B | HOFFMANN LA ROCHE (CH) | 2005-07-20 | — | — | CN | disclosed |
| US-6903095-B2 | Nitrogen compounds such as 2-(5-(4-Fluoro-benzyloxy)-1,3-dioxo -1,3-dihydro-isoindol-2-yl)-acetamide, used for prophylaxis of Alzheimer's disease; amine oxidase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2005-06-07 | — | — | US | disclosed |
| EP-1490334-A1 | PHTHALIMIDO DERIVATIVES AS INHIBITORS OF MONOAMINE OXIDASE B | F. HOFFMANN-LA ROCHE AG (CH) | 2004-12-29 | — | — | EP | disclosed |
| US-20040229871-A1 | Phthalimido derivatives and a process for their preparation | CESURA ANDREA (CH) | 2004-11-18 | — | — | US | disclosed |
| US-6660736-B2 | MAO-B inhibitors | HOFFMANN-LA ROCHE INC. | 2003-12-09 | — | — | US | disclosed |
| US-20030195208-A1 | PHTHALIMIDO DERIVATIVES AND A PROCESS FOR THEIR PREPARATION | HOFFMANN-LA ROCHE INC. | 2003-10-16 | — | — | US | disclosed |
| WO-2003080573-A1 | PHTHALIMIDO DERIVATIVES AS INHIBITORS OF MONOAMINE OXIDASE B | F. HOFFMANN-LA ROCHE AG (CH) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195208-A1 | PHTHALIMIDO DERIVATIVES AND A PROCESS FOR THEIR PREPARATION | MAOB, MAOA, CYP4B1 | MEN1 1030/4885KMT2A 522/4885ANPEP 2291/4885 |
| US-20040229871-A1 | Phthalimido derivatives and a process for their preparation | MAOB, MAOA, CYP4B1 | MEN1 1030/4885KMT2A 522/4885ANPEP 2291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.